Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR)

被引:45
作者
Beaufort, N
Debela, M
Creutzburg, S
Kellermann, J
Bode, W
Schmitt, M
Pidard, D
Magdolen, V [1 ]
机构
[1] Tech Univ Munich, Klin Forschergruppe Frauenklin, D-81675 Munich, Germany
[2] Inst Pasteur, INSERM, Unite Defense Innee & Inflammat, E0336,Dept Mol Med, F-75015 Paris, France
[3] Max Planck Inst Biochem, Abt Strukturforschung, D-82152 Martinsried, Germany
[4] Max Planck Inst Biochem, Abt Proteinanaly, D-82152 Martinsried, Germany
关键词
enamel matrix serine protease 1; invasion; metastasis; prostase; tumor-associated proteolytic system;
D O I
10.1515/BC.2006.029
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The plasminogen activation system is involved in cancer progression and metastasis. Among other proteolytic factors, it includes the serine protease urokinase-type plasminogen activator (uPA) and its three-domain (D1D2D3) receptor uPAR (CD87), which focuses plasminogen activation to the cell surface. The function of uPAR is regulated in part through shedding of domain D1 by proteases, e. g., uPA itself or plasmin. Human tissue kallikrein 4 (hK4), which is highly expressed in prostate and ovarian tumor tissue, was previously shown to cleave and activate the pro-enzyme forms of prostate-specific antigen (PSA, tissue kallikrein hK3) and uPA. Here we demonstrate that uPAR is also a target for hK4, being cleaved in the D1-D2 linker sequence and, to a lesser extent, in its D3 juxtamembrane domain. hK4 may thus modulate the tumor-associated uPA/uPAR-system activity by either activating the pro-enzyme form of uPA or cleaving the cell surface-associated uPA receptor.
引用
收藏
页码:217 / 222
页数:6
相关论文
共 32 条
[21]   Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor [J].
Ploug, M .
CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (19) :1499-1528
[22]   Urokinase receptor: a molecular organizer in cellular communication [J].
Preissner, KT ;
Kanse, SM ;
May, AE .
CURRENT OPINION IN CELL BIOLOGY, 2000, 12 (05) :621-628
[23]   Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins [J].
Reuning, U ;
Magdolen, V ;
Hapke, S ;
Schmitt, M .
BIOLOGICAL CHEMISTRY, 2003, 384 (08) :1119-1131
[24]   Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo [J].
Sidenius, N ;
Sier, CFM ;
Blasi, F .
FEBS LETTERS, 2000, 475 (01) :52-56
[25]   Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization [J].
Sidenius, N ;
Andolfo, A ;
Fesce, R ;
Blasi, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (31) :27982-27990
[26]   Purification, characterization, and cloning of enamel matrix serine proteinase 1 [J].
Simmer, JP ;
Fukae, M ;
Tanabe, T ;
Yamakoshi, Y ;
Uchida, T ;
Xue, J ;
Margolis, HC ;
Shimizu, M ;
DeHart, BC ;
Hu, CC ;
Bartlett, JD .
JOURNAL OF DENTAL RESEARCH, 1998, 77 (02) :377-386
[27]   Kallikrein 4 is a secreted protein [J].
Simmer, JP ;
Bartlett, JD .
CANCER RESEARCH, 2004, 64 (22) :8481-8482
[28]   The uPA/uPA receptor system as a target for tumor therapy [J].
Sperl, S ;
Mueller, MM ;
Wilhelm, OG ;
Schmitt, M ;
Magdolen, V ;
Moroder, L .
DRUG NEWS & PERSPECTIVES, 2001, 14 (07) :401-411
[29]   Characterization of hK4 (prostase), a prostate-specific serine protease: Activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase [J].
Takayama, TK ;
McMullen, BA ;
Nelson, PS ;
Matsumura, M ;
Fujikawa, K .
BIOCHEMISTRY, 2001, 40 (50) :15341-15348
[30]   Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer [J].
Xi, ZJ ;
Klokk, TI ;
Korkmaz, K ;
Kurys, P ;
Elbi, C ;
Risberg, B ;
Danielsen, H ;
Loda, M ;
Saatcioglu, F .
CANCER RESEARCH, 2004, 64 (07) :2365-2370